← Back to Companies

Jnana Therapeutics

Biotechnology company developing small molecule therapeutics for metabolic and rare diseases by targeting solute carrier (SLC) transporters using its proprietary RAPID platform.

Location
Boston, Massachusetts, USA
Founded
2018
Categories
biotech, drug-discovery, metabolic-disease, cardiovascular, rare-disease, small-molecule

Notes

Jnana Therapeutics is a biotechnology company focused on developing small molecule therapeutics that target solute carrier (SLC) transporters. SLCs are membrane proteins that control the movement of nutrients, metabolites, and other molecules across cell membranes, and represent a largely untapped class of drug targets.

The company's proprietary RAPID (Reactive Affinity Probe-based Interaction Discovery) platform enables the discovery of compounds that modulate SLC transporter function. Jnana is developing therapeutics for metabolic diseases, rare genetic disorders, and other conditions where SLC dysfunction plays a role.

Founded in 2018, Jnana has built a pipeline focused on conditions including phenylketonuria (PKU), gout, and immunometabolic diseases.

Team

  • Joanne Kotz, Ph.D. - CEO & Co-founder
  • Mark Bhaskaran - Chief Scientific Officer & Co-founder
  • Team with expertise in metabolic diseases and drug discovery

Additional Research Findings

  • Founded in 2018, headquartered in Boston, Massachusetts
  • RAPID platform for SLC transporter drug discovery
  • Targets solute carrier (SLC) transporters
  • Lead programs for PKU (phenylketonuria), gout
  • Small molecule therapeutics
  • Raised significant venture capital funding
  • Backed by Atlas Venture, GV, and others
  • Novel approach to historically difficult targets
  • Pipeline includes rare and metabolic diseases

Sources